Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P04198: Variant p.Thr58Met

N-myc proto-oncogene protein
Gene: MYCN
Feedback?
Variant information Variant position: help 58 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Threonine (T) to Methionine (M) at position 58 (T58M, p.Thr58Met). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (T) to medium size and hydrophobic (M) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In MPAPA; pathogenic; mice with the orthologous mutation have polydactyly and higher brain weight than wild-type animals; results in loss of T-58 phosphorylation; results in increased protein levels. Any additional useful information about the variant.


Sequence information Variant position: help 58 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 464 The length of the canonical sequence.
Location on the sequence: help GGPDSTPPGEDIWKKFELLP T PPLSPSRGFAEHSSEPPSWV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         GGPDSTPPGEDIWKKFELLPTPPLSPSRGFAEHSS-------------------EPPSWV

Mouse                         GGPDSTPPGEDIWKKFELLPTPPLSPSRAFPEHSP------

Rat                           GGPDSTPPGEDIWKKFELLPTPPLSPSRAFPEHSP------

Chicken                       CGPDSAPPGEDIWKKFELLPTPPLSPSRAGLQEPPPGGGSI

Xenopus laevis                CDPDSAPPGEDIWKKFELLPTPPLSPSRSGLHGDP------
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 464 N-myc proto-oncogene protein
Modified residue 58 – 58 Phosphothreonine
Mutagenesis 73 – 73 E -> K. Reduces binding to AURKA.
Mutagenesis 77 – 77 W -> A. Reduces binding to AURKA.



Literature citations
MYCN de novo gain-of-function mutation in a patient with a novel megalencephaly syndrome.
Kato K.; Miya F.; Hamada N.; Negishi Y.; Narumi-Kishimoto Y.; Ozawa H.; Ito H.; Hori I.; Hattori A.; Okamoto N.; Kato M.; Tsunoda T.; Kanemura Y.; Kosaki K.; Takahashi Y.; Nagata K.I.; Saitoh S.;
J. Med. Genet. 56:388-395(2019)
Cited for: VARIANT MPAPA MET-58; CHARACTERIZATION OF VARIANT MPAPA MET-58; INVOLVEMENT IN MPAPA; PHOSPHORYLATION AT THR-58;
Gain-of-function MYCN causes a megalencephaly-polydactyly syndrome manifesting mirror phenotypes of Feingold syndrome.
Nishio Y.; Kato K.; Tran Mau-Them F.; Futagawa H.; Quelin C.; Masuda S.; Vitobello A.; Otsuji S.; Shawki H.H.; Oishi H.; Thauvin-Robinet C.; Takenouchi T.; Kosaki K.; Takahashi Y.; Saitoh S.;
HGG Adv. 4:100238-100238(2023)
Cited for: VARIANTS MPAPA MET-58 AND LEU-60; CHARACTERIZATION OF VARIANTS MPAPA MET-58 AND LEU-60; INVOLVEMENT IN MPAPA;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.